These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 1655118)

  • 1. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
    Utsugi T; Mattern MR; Mirabelli CK; Hanna N
    Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
    Liu LF; D'Arpa P
    Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
    [No Abstract]   [Full Text] [Related]  

  • 9. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
    Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
    Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
    Andrea JE; Adachi K; Morgan AR
    Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
    Vassetzky YS; Alghisi GC; Gasser SM
    Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells.
    Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK
    Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
    Utsugi T; Demuth S; Hanna N
    Cancer Res; 1989 Mar; 49(6):1429-33. PubMed ID: 2538225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
    Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
    Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
    de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
    Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.